Page 230 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology FN3K–Nrf2 axis inhibition in breast cancer

Conflict of interest Cell. 2019;178(4):807-819.e21.

The authors have no relevant financial or non-financial doi: 10.1016/j.cell.2019.07.031
interests to disclose. 5. Beeraka NM, Zhang J, Mandal S, et al. Screening
fructosamine-3-kinase (FN3K) inhibitors, a deglycating
Author contributions enzyme of oncogenic Nrf2: Human FN3K homology
Conceptualization: Gurupadayya Bannimath, Prabitha modelling, docking and molecular dynamics simulations.
Prabhakaran PLoS One. 2023;18(11):e0283705.
Data curation: Erica Alves doi: 10.1371/journal.pone.0283705
Formal analysis: Erica Alves, Prabitha Prabhakaran 6. Beeraka NM, Zhang J, Uthaiah CA, et al. Expression patterns
Investigation: Erica Alves and relevance of FN3K, Nrf2, and NQO1 in breast cancers.
Methodology: Erica Alves Eurasian J Med Oncol. 2024;8(1):88-105.
Software: Erica Alves doi: 10.14744/ejmo.2024.61033
Validation: Erica Alves, Prabitha Prabhakaran
Writing – original draft: Erica Alves 7. Delpierre G, Collard F, Fortpied J, Van Schaftingen E.
Writing – review & editing: Erica Alves Fructosamine 3-kinase, an enzyme involved in protein
deglycation. Biochem Soc Trans. 2004;32(6):813-816.
Ethics approval and consent to participate doi: 10.1042/bst0320813
Not applicable. 8. Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-
based virtual screening for drug discovery: Principles,
Consent for publication applications and recent advances. Curr Top Med Chem.
Not applicable. 2014;14(16):1923-1938.
doi: 10.2174/1568026614666140929124445
Availability of data
9. Roskoski R Jr. Properties of FDA-approved small molecule
All data generated or analyzed during this study protein kinase inhibitors: A 2023 update. Pharmacol Res.
are included in this published article and its 2023;187:106552.
supplementary files, which can be accessed in doi: 10.1016/j.phrs.2023.106552
https://docs.google.com/document/d/1KTlZz
Q XsT etJk5wV h7H y w6cd w6UK0HR l/ 10. Beeraka NM, Bovilla VR, Doreswamy SH, Puttalingaiah S,
edit?usp=sharing&ouid=1037173611445693706 Srinivasan A, Madhunapantula SV. The taming of nuclear
02&rtpof=true&sd=true Additional datasets supporting factor erythroid-2-related factor-2 (Nrf2) deglycation by
the findings of this study are available from the fructosamine-3-kinase (FN3K)-inhibitors-a novel strategy
corresponding author upon reasonable request. to combat cancers. Cancers (Basel). 2021;13(2):281.
doi: 10.3390/cancers13020281
References
11. Beeraka NM, Zhang J, Zhao D, et al. Combinatorial
1. Tufail M, Jiang CH, Li N. Altered metabolism in cancer: implications of Nrf2 inhibitors with FN3K inhibitor: In vitro
Insights into energy pathways and therapeutic targets. Mol breast cancer study. Curr Pharm Des. 2023;29(30):2408-2425.
Cancer. 2024;23(1):203.
doi: 10.2174/0113816128261466231011114600
doi: 10.1186/s12943-024-02119-3
12. Carles F, Bourg S, Meyer C, Bonnet P. PKIDB: A curated,
2. Yousefi T, Pasha ARG, Kamrani G, et al. Evaluation annotated and updated database of protein kinase inhibitors
of fructosamine 3-kinase and glyoxalase 1 activity in in clinical trials. Molecules. 2018;23(4):908.
normal and breast cancer tissues. Biomedicine (Taipei).
2021;11(3):15-22. doi: 10.3390/molecules23040908
doi: 10.37796/2211-8039.1130 13. World Health Organization. WHO Model Lists of Essential
Medicines. 23 List; 2023. Available from: https://www.who.
rd
3. Alves E, Bannimath G, Prabhakaran P, Beeraka NM. The int/publications/i/item/WHO-MHP-HPS-EML-2023.01
FN3K-Nrf2 axis: A novel therapeutic target in cancer [Last accessed on 2025 Mar 14].
metabolism. Eurasian J Med Oncol. 2024;8(4):338-339.
14. National Cancer Institute. Breast Cancer Treatment Drugs.
doi: 10.14744/ejmo.2024.20665 Bethesda, MD: National Cancer Institute. Available from:
4. Sanghvi VR, Leibold J, Mina M, et al. The oncogenic action https://www.cancer.gov/about-cancer/treatment/drugs/
of NRF2 depends on de-glycation by fructosamine-3-kinase. breast [Last accessed on 2025 Mar 14].

Volume 9 Issue 3 (2025) 222 doi: 10.36922/EJMO025150114